SCHEMBL2136972

SCHEMBL2136972

Cc1c(C#N)ccnc1Br

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.36
TSHR P16473 1/20 0.35
NOS3 P29474 2/20 0.34
NOS2 P35228 2/20 0.34
LRRK2 Q5S007 5/20 0.34
ROCK2 O75116 2/20 0.34
ROCK1 Q13464 2/20 0.34
CDC42BPA Q5VT25 2/20 0.34
CDC42BPB Q9Y5S2 2/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EGLN2 Q96KS0 1/20 0.33
NTRK1 P04629 1/20 0.33
PIM1 P11309 1/20 0.33
ACVR1 Q04771 1/20 0.33
AR P10275 1/20 0.33
TGFBR1 P36897 1/20 0.31
HCRTR1 O43613 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22647247 0.79 NOS2 (0.54) NISCHTSHRNOS3NOS2LRRK2
SCHEMBL3671909 0.78 TSHR (0.38) NISCHTSHRNOS3NOS2LRRK2
SCHEMBL17570530 0.77 TSHR (0.37) NISCHTSHRNOS3NOS2LRRK2
SCHEMBL1119092 0.75 FFAR1 (0.42) NISCHTSHRLRRK2ROCK2ROCK1
SCHEMBL30900904 0.75 EGLN2 (0.39) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL27096722 0.75 EGLN2 (0.39) LRRK2ROCK2ROCK1CDC42BPACDC42BPB
SCHEMBL15758260 0.75 FFAR1 (0.42) NISCHTSHRLRRK2ROCK2ROCK1
SCHEMBL11285134 0.75 AR (0.36) NISCHTSHRLRRK2ROCK2ROCK1
SCHEMBL19564466 0.72 NISCH (0.37) NISCHTSHRLRRK2ROCK2ROCK1
SCHEMBL17859388 0.72 HSD17B10 (0.38) NISCHTSHRNOS3NOS2LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2445891-A1 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS Glaxo Group Limited (GB) 2012-05-02 EP disclosed
US-20120101134-A1 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2012-04-26 US disclosed
WO-2010148649-A1 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS GLAXO GROUP LIMITED (GB) 2010-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101134-A1 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS S1PR1, S1PR5, S1PR3 NISCH 2750/4885TSHR 223/4885NOS3 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.